Please ensure Javascript is enabled for purposes of website accessibility

What Investors Need to Know From Pfizer's Earnings Report

By Adria Cimino – Updated Jun 23, 2021 at 8:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has to do with getting a step ahead of the coronavirus.

Pfizer (PFE 0.87%) recently reported earnings -- and gave a very positive update regarding what to expect from its coronavirus vaccine this year. In this Motley Fool Live video recorded on May 28, 2021, Healthcare and Cannabis Bureau Editor and Analyst Olivia Zitkus and contributor Adria Cimino discuss the news in Pfizer's earnings report that may signal major ongoing success for the vaccine.

Olivia Zitkus: From Pfizer's recent earnings report, I'm wondering if anything besides some of their conversations and their new expanded authorization -- What stood out to you from that report? Anything in particular that investors need to be keeping an eye on or watch in the future?

Adria Cimino: From the earnings report, I would say the regulatory pathway of 100 days to update the vaccine. Because they were really talking about the idea that in the future, if they have to change this vaccine, how much time to get it changed and updated, and as we see with the variants, I think this is very important. We need to know that this could be done quickly because if they couldn't, then it could really represent a big threat. It's key to get the right vaccine out there as these variants gain ground. You might say well, Pfizer is a huge company, could this really mean a whole lot? They've tons of products out there and everything, but actually Pfizer expects $26 billion in vaccine revenue this year, and then they have to split that with BioNTech, their partner. But still, it represents a big deal for Pfizer. They expect vaccine revenue to make up 36% of this year's revenue, and that's up from an earlier estimate of 25%. So really this is a big product for Pfizer, it really is, and so it's key that they keep on top of this, and get it right each time.

Olivia Zitkus: Exactly. It's good for good public health news and the investors, all that.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$44.14 (0.87%) $0.38
BioNTech SE Stock Quote
BioNTech SE
$136.68 (1.33%) $1.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.